Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
RANDOMIZED COMPARISON OF MEROPENEM WITH CEFOTAXIME FOR TREATMENT OF BACTERIAL-MENINGITIS
Autore:
KLUGMAN KP; DAGAN R; WILLIAMS KJ; FEATHERSTONE A; BEATTY D; LEARY M; WALKER K; RODDA J; SCHER G; HOUSEHAM C; PELSAR H; LOPEZ E; FALLO L; TREGNAGHI MW; AIRD A; DEAPRA EQ; BEGUE P; BOULESTEIX J; FLORET D; ASTRUC J; BOUILLE C; CARRIERE JP;
Indirizzi:
S AFRICAN INST MED RES,DEPT MED MICROBIOL,POB 1038 JOHANNESBURG SOUTHAFRICA UNIV WITWATERSRAND,DEPT MED MICROBIOL,MRC,PNEUMOCOCCAL DIS RES UNIT JOHANNESBURG SOUTH AFRICA BEN GURION UNIV NEGEV,FAC HLTH SCI BEER SHEVA ISRAEL BEN GURION UNIV NEGEV,SOROKA MED CTR,PEDIAT INFECT DIS UNIT IL-84105 BEER SHEVA ISRAEL
Titolo Testata:
Antimicrobial agents and chemotherapy
fascicolo: 5, volume: 39, anno: 1995,
pagine: 1140 - 1146
SICI:
0066-4804(1995)39:5<1140:RCOMWC>2.0.ZU;2-6
Fonte:
ISI
Lingua:
ENG
Soggetto:
BETA-LACTAM ANTIBIOTICS; IMIPENEM-CILASTATIN; STREPTOCOCCUS-PNEUMONIAE; RESISTANT PNEUMOCOCCUS; CHILDREN; THERAPY; FAILURE; INVITRO;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
28
Recensione:
Indirizzi per estratti:
Citazione:
K.P. Klugman et al., "RANDOMIZED COMPARISON OF MEROPENEM WITH CEFOTAXIME FOR TREATMENT OF BACTERIAL-MENINGITIS", Antimicrobial agents and chemotherapy, 39(5), 1995, pp. 1140-1146

Abstract

Broad-spectrum cephalosporins are drugs of choice for the treatment of meningitis in communities which can afford them. The emergence of cephalosporin-resistant pneumococci demands the clinical trial of alternate agents. Carbapenems are active against the bacteria causing meningitis, but the use of imipenem-cilastatin was frustrated by drug-associated seizures. The safety and efficacy of meropenem, a new carbapenem,were compared to those of cefotaxime in a prospective randomized trial of 190 children with bacterial meningitis. Seizures occurred within 24 h before antibiotic therapy in 16 of 98 patients (16%) randomized to receive meropenem and in 6 of 92 patients (7%) randomized to receivecefotaxime. In patients without seizures before therapy, seizures occurred during therapy in 5 of 82 patients (6%) receiving meropenem and in 1 of 86 patients (1%) receiving cefotaxime (95% confidence interval: -0.7%, 10.6%). None were thought to be drug related. Twenty-four meropenem-treated patients (24%) and 11 cefotaxime-treated patients (12%)had neurological abnormalities before therapy. In patients without pretherapy neurological abnormalities, these abnormalities were present after treatment in 4 of 74 meropenem-treated patients (5%) and in 2 of81 cefotaxime-treated patients (2%) (95% confidence interval: -3.2%, 9.1%). Of 75 meropenem-treated and 64 cefotaxime-treated patients withpretherapy positive cerebrospinal-fluid cultures, 68 and 59, respectively, had repeat lumbar punctures. Bacterial eradication was found to be 100% in both groups. Our data suggest that meropenem may be a carbapenem agent that is well tolerated and effective in the treatment of bacterial meningitis.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/12/20 alle ore 10:47:03